Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.26), $0.43 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $191.2 million versus the consensus estimate of $193.46 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.